Ardent Health, Inc. (NYSE:ARDT – Get Free Report)’s stock price hit a new 52-week low during mid-day trading on Tuesday after JPMorgan Chase & Co. lowered their price target on the stock from $12.00 to $11.00. JPMorgan Chase & Co. currently has a neutral rating on the stock. Ardent Health traded as low as $8.26 and last traded at $8.2550, with a volume of 220293 shares traded. The stock had previously closed at $8.60.
Several other analysts have also recently weighed in on ARDT. Stephens dropped their price target on Ardent Health from $21.00 to $17.00 and set an “overweight” rating for the company in a report on Friday, November 14th. Truist Financial lowered their price objective on Ardent Health from $21.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, November 14th. KeyCorp downgraded Ardent Health from an “overweight” rating to a “sector weight” rating in a report on Monday, November 17th. Mizuho reduced their target price on shares of Ardent Health from $20.00 to $12.00 and set an “outperform” rating for the company in a research report on Thursday, December 18th. Finally, The Goldman Sachs Group assumed coverage on shares of Ardent Health in a research report on Tuesday, October 14th. They set a “neutral” rating and a $19.00 price target on the stock. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Ardent Health currently has a consensus rating of “Hold” and an average price target of $14.58.
Read Our Latest Stock Report on ARDT
Key Headlines Impacting Ardent Health
- Positive Sentiment: Bull case: A bullish thesis published and summarized by third-party sites highlights ARDT’s low trailing and forward P/E and argues the shares may be undervalued, which could attract value-oriented buyers if legal headlines cool. Ardent Health, Inc. (ARDT): A Bull Case Theory
- Neutral Sentiment: Analyst action: JPMorgan cut its price target from $12 to $11 and kept a “neutral” rating; the lower PT reduces near-term analyst support but still implies upside versus current levels. Benzinga: JPMorgan PT Cut
- Neutral Sentiment: Broker consensus: Major brokerage coverage shows a consensus “Hold” recommendation, which signals limited near-term buy-side institutional enthusiasm until legal and operational clarity improves. Consensus “Hold”
- Negative Sentiment: Class-action filings — securities firms: Multiple national plaintiff firms (Bleichmar Fonti & Auld / BFA Law, Hagens Berman, Rosen, Pomerantz, Wolf Haldenstein, Faruqi & Faruqi) have announced or filed securities class actions alleging ARDT misled investors about revenue recognition and professional liability reserves after a sharp stock drop. These actions increase litigation risk, potential future settlements and management distraction. BFA Law class action notice Hagens Berman notice Pomerantz investor alert
- Negative Sentiment: Additional plaintiff outreach: Several other firms (Wolf Haldenstein, Rosen, Faruqi & Faruqi) are notifying investors and seeking lead plaintiffs ahead of a March 9, 2026 deadline — this amplifies visibility, keeps the stock under pressure and may prompt sellers ahead of potential discovery/settlement risk. Rosen Law notice Wolf Haldenstein alert Faruqi & Faruqi notice
Institutional Investors Weigh In On Ardent Health
Several institutional investors and hedge funds have recently bought and sold shares of ARDT. Voleon Capital Management LP bought a new position in Ardent Health in the 3rd quarter valued at about $571,000. Verition Fund Management LLC boosted its position in shares of Ardent Health by 540.6% during the 3rd quarter. Verition Fund Management LLC now owns 85,561 shares of the company’s stock worth $1,134,000 after acquiring an additional 72,205 shares in the last quarter. Prelude Capital Management LLC increased its stake in Ardent Health by 30.3% in the third quarter. Prelude Capital Management LLC now owns 18,303 shares of the company’s stock valued at $243,000 after acquiring an additional 4,259 shares during the last quarter. Millennium Management LLC raised its position in Ardent Health by 6.6% during the third quarter. Millennium Management LLC now owns 1,269,605 shares of the company’s stock valued at $16,822,000 after purchasing an additional 78,861 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in Ardent Health by 2.5% during the third quarter. Bank of America Corp DE now owns 310,563 shares of the company’s stock worth $4,115,000 after purchasing an additional 7,610 shares during the last quarter.
Ardent Health Stock Performance
The stock has a fifty day simple moving average of $9.08 and a two-hundred day simple moving average of $11.69. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.95 and a current ratio of 2.08. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of 5.71, a P/E/G ratio of 4.91 and a beta of 0.72.
Ardent Health (NYSE:ARDT – Get Free Report) last announced its quarterly earnings data on Wednesday, November 12th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.42 by $0.10. The business had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.55 billion. Ardent Health had a return on equity of 19.02% and a net margin of 3.24%.Ardent Health has set its FY 2025 guidance at 0.850-1.030 EPS. Analysts expect that Ardent Health, Inc. will post 1.23 EPS for the current fiscal year.
Ardent Health Company Profile
Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.
Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.
See Also
- Five stocks we like better than Ardent Health
- Trump’s AI Secret: 100X Faster Than Nvidia
- Wall Street Alert: Buy AES
- Do not delete, read immediately
- Refund From 1933: Trump’s Reset May Create Instant Wealth
- The Crash Has Already Started (Most Just Don’t See It Yet)
Receive News & Ratings for Ardent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardent Health and related companies with MarketBeat.com's FREE daily email newsletter.
